行政索赔数据中药物难治性癫痫定义
本研究从三级医疗系统随机抽取450例癫痫患者,基于电子病历和2010年ILAE标准评估药物难治性癫痫,并建立行政索赔数据定义。300例纳入分析中98例(33%)符合当前药物难治性癫痫。研究提出三种索赔定义,分别优化总体预测、敏感性和特异性,可用于不同研究问题。
要点
- 药物难治性癫痫诊断代码是当前药物难治性癫痫最强预测因子(OR 16.9)。
- 优化总体预测的定义敏感性0.86、特异性0.74、AUROC 0.80。
- 优化敏感性的定义敏感性0.98、特异性0.47、AUROC 0.72。
核心结论
- 多种基于行政索赔数据的药物难治性癫痫定义得到验证,可适用于不同研究问题。
研究设计与样本
- 从三级医疗系统随机抽取450例有癫痫/惊厥就诊、2014至2020年至少2种不同抗癫痫药物且至少2年电子病历数据的患者。
- 最终300例纳入分析,通过病历回顾和基于2010年国际抗癫痫联盟定义的评分标准确定药物难治性癫痫诊断。
主要发现
- 300例患者中98例(33%)符合当前药物难治性癫痫标准。
- 当前药物难治性癫痫的最强预测因子包括药物难治性癫痫诊断代码(OR 16.9,95%CI 8.8-32.2)、既往2年内至少2种抗癫痫药物(OR 13.0,95%CI 5.1-33.3)、至少3种非加巴喷丁类抗癫痫药物(OR 10.3,95%CI 5.4-19.6)、神经外科就诊(OR 45.2,95%CI 5.9-344.3)和癫痫手术(OR 30.7,95%CI 7.1-133.3)。
关键数值与推荐
- 优化总体预测的定义:药物难治性癫痫诊断,敏感性0.86,特异性0.74,AUROC 0.80。
- 优化敏感性的定义:药物难治性癫痫诊断或至少3种抗癫痫药物,敏感性0.98,特异性0.47,AUROC 0.72。
- 优化特异性的定义:药物难治性癫痫诊断且至少3种非加巴喷丁类抗癫痫药物,敏感性0.42,特异性0.98,AUROC 0.70。
临床怎么用
- 临床研究中可根据研究目的选择不同索赔定义:需高敏感性时选用诊断或至少3种抗癫痫药物定义,需高特异性时选用诊断且至少3种非加巴喷丁类抗癫痫药物定义。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVE: To assess the accuracy of definitions of drug-resistant epilepsy applied to administrative claims data. METHODS: We randomly sampled 450 patients from a tertiary health system with ≥1 epilepsy/convulsion encounter, ≥2 distinct antiseizure medications (ASMs) from 2014 to 2020, and ≥2 years of electronic medical records (EMR) data. We established a drug-resistant epilepsy diagnosis at a specific visit by reviewing EMR data and using a rubric based on the 2010 International League Against Epilepsy definition. We performed logistic regressions to assess clinically relevant predictors of drug-resistant epilepsy and to inform claims-based definitions. RESULTS: Of 450 patients reviewed, 150 were excluded for insufficient EMR data. Of the 300 patients included, 98 (33%) met criteria for current drug-resistant epilepsy. The strongest predictors of current drug-resistant epilepsy were drug-resistant epilepsy diagnosis code (odds ratio [OR] 16.9, 95% confidence interval [CI] 8.8-32.2), ≥2 ASMs in the prior 2 years (OR 13.0, 95% CI 5.1-33.3), ≥3 nongabapentinoid ASMs (OR 10.3, 95% CI 5.4-19.6), neurosurgery visit (OR 45.2, 95% CI 5.9-344.3), and epilepsy surgery (OR 30.7, 95% CI 7.1-133.3). We created claims-based drug-resistant epilepsy definitions (1) to maximize overall predictiveness (drug-resistant epilepsy diagnosis; sensitivity 0.86, specificity 0.74, area under the receiver operating characteristics curve [AUROC] 0.80), (2) to maximize sensitivity (drug-resistant epilepsy diagnosis or ≥3 ASMs; sensitivity 0.98, specificity 0.47, AUROC 0.72), and (3) to maximize specificity (drug-resistant epilepsy diagnosis and ≥3 nongabapentinoid ASMs; sensitivity 0.42, specificity 0.98, AUROC 0.70). DISCUSSION: Our findings provide validation for several claims-based definitions of drug-resistant epilepsy that can be applied to a variety of research questions.
引用
- Hill CE, Lin CC, Terman SW, et al. Definitions of Drug-Resistant Epilepsy for Administrative Claims Data Research. Neurology. 2021. PMID: 34266920. doi:10.1212/WNL.0000000000012514
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。